Trials / Completed
CompletedNCT02780323
Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis
A Multi-center, Double-blind, Active-controlled, Randomized, Parallel-group Clinical Trial to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This Phase IV clinical study is to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Rheumatoid Arthritis Patients
Detailed description
Thisi is a multi-center, double-blind, active-controlled, randomized, parallel-group clinical trial to compare the efficacy and safety of CELBESTA® and CELEBREX® in patients with rheumatoid arthritis. The subject will receive two tablets twice daily for 6 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CELBESTA® | 1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks |
| DRUG | CELEBREX® | 1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks |
| DRUG | CELEBREX® placebo | 1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks |
| DRUG | CELBESTA® placebo | 1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks |
Timeline
- Start date
- 2015-11-02
- Primary completion
- 2017-12-26
- Completion
- 2017-12-26
- First posted
- 2016-05-23
- Last updated
- 2020-02-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02780323. Inclusion in this directory is not an endorsement.